CCR2 Antagonist 1PC X 5MG

Description General description A cis-diamidocyclohexyl urea compound that potently competes against MCP-1 binding to CCR2 (IC50 = 5.1 nM) and effectively inhibits MCP-1/CCR2-mediated PBMCs Ca+2 flux and chemotaxis (IC50 = 18 and 1 nM, respectively), while showing much less effect against eotaxin binding to CCR3 (37% inhibition at 10 µM). Mutageneis analysis indicates CCR2 Thr292 is critical in maintaining the high affinity antagonist binding. Packaging 5 mg in Plastic ampoule Packaged under inert gas Warning Toxicity: Standard Handling (A) Preparation Note Gentle warming, rapid stirring, and/or sonication may be required for complete solubilization. Reconstitution Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C. Other Notes Cherney, R.J., et al. 2008. J. Med. Chem.51, 721.; Description